España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

b braun medical s.a. - bupivacaina hidrocloruro - soluciÓn inyectable - 7,5 mg/ml inyectable 10 ml - bupivacaina hidrocloruro 7.5 mg - bupivacaína

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

b braun medical s.a. - bupivacaina hidrocloruro - soluciÓn inyectable - 2,5 mg/ml inyectable 10 ml - bupivacaina hidrocloruro 2.5 mg - bupivacaína

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

inretail pharma s.a. - l-leucina; l-isoleucina; l-valina; l-glutamina; l- citrulina; beta alanina; - polvo para suspension oral - por otros13 g; l-glutamina 3.510000 mg; l-isoleucina 1.752000 mg; l-leucina 3.504000 mg; l-valina 1.752000 mg; l- citrulina 0.299000 mg; beta alanina 0.200000 mg; - aminoácidos

Chile - español - ISPC (Instituto de Salud Pública de Chile)

ecolab spa - sin formulas

Chile - español - ISPC (Instituto de Salud Pública de Chile)

ecolab spa - sin formulas

Unión Europea - español - EMA (European Medicines Agency)

sanofi winthrop industrie - clopidogrel - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - agentes antitrombóticos - prevención secundaria de aterotrombótico eventsclopidogrel está indicado en:pacientes adultos que sufren de infarto de miocardio (desde pocos días hasta menos de 35 días), el accidente cerebrovascular isquémico (desde 7 días hasta menos de 6 meses) o enfermedad arterial periférica establecida. los pacientes adultos que sufren de síndrome coronario agudo:sin elevación del segmento st síndrome coronario agudo (angina inestable o no-q onda infarto de miocardio), incluyendo pacientes sometidos a colocación de un stent tras la intervención coronaria percutánea, en combinación con ácido acetilsalicílico (aas). st segment elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event. prevención de aterotrombóticos y tromboembólicos eventos en la fibrillationin pacientes adultos con fibrilación auricular que tienen al menos un factor de riesgo de eventos vasculares, no son adecuados para el tratamiento con antagonistas de la vitamina k (vka) y que tienen un bajo riesgo de sangrado, clopidogrel está indicado en combinación con aas para la prevención de la aterotrombótico y eventos tromboembólicos, incluyendo infarto cerebral.

Unión Europea - español - EMA (European Medicines Agency)

sanofi winthrop industrie - sulfato de hidrógeno y clopidogrel - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - agentes antitrombóticos - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event. prevención de aterotrombóticos y tromboembólicos eventos en la fibrillationin pacientes adultos con fibrilación auricular que tienen al menos un factor de riesgo de eventos vasculares, no son adecuados para el tratamiento con vitamina k antagonistas y que tienen un bajo riesgo de sangrado, clopidogrel está indicado en combinación con aas para la prevención de la aterotrombótico y eventos tromboembólicos, incluyendo infarto cerebral.

Unión Europea - español - EMA (European Medicines Agency)

acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - agentes antitrombóticos - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

Unión Europea - español - EMA (European Medicines Agency)

taw pharma (ireland) limited - clorhidrato de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agentes antitrombóticos - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Unión Europea - español - EMA (European Medicines Agency)

sanofi winthrop industrie - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - agentes antitrombóticos - duoplavin está indicado para la prevención secundaria de eventos aterotrombóticos en pacientes adultos que ya toman tanto clopidogrel como ácido acetilsalicílico (asa). duoplavin is a fixed-dose combination medicinal product for continuation of therapy in:non st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (pci);st segment elevation acute myocardial infarction (stemi) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. para más información, por favor refiérase a la sección 5.